Tuspetinib is under clinical development by Aptose Biosciences and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData, Phase II drugs for Chronic Myelomonocytic Leukemia (CMML) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tuspetinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tuspetinib overview
Tuspetinib (HM-43239) is under development for the treatment of relapsed and refractory acute myeloid leukemia, relapsed/refractory high risk myelodysplastic syndrome (HR-MDS) and chronic myelomonocytic leukemia (CMML). The drug candidate is administered through oral route in the form of tablet. It acts by targeting FMS-like tyrosine kinase 3 (FLT3), spleen tyrosine kinase (SYK), Janus Kinase 1 and 2 (JAK1/2), tyrosine protein kinase c KIT, ribosomal protein S6 kinase (RSK2), TGF-beta-activated kinase 1 (MAP3K7/TAK1/TAB1).
Aptose Biosciences overview
Aptose Biosciences (Aptose) is a clinical-stage biotechnology company. It develops innovative medicines to address unmet clinical needs in oncology, with a focus on hematology. The company’s product pipeline includes two oral kinase inhibitors: tuspetinib (HM43239) and luxeptinib (CG-806). Tuspetinib is being evaluated for frontline therapy in newly diagnosed acute myeloid leukemia (AML) and has demonstrated complete responses in relapsed or refractory AML patients. It is also being explored in combination with venetoclax. Luxeptinib targets kinases in myeloid and lymphoid malignancies and has shown tumor shrinkage in trials for relapsed B-cell leukemias. Aptose is headquartered in Toronto, Ontario, Canada.
For a complete picture of Tuspetinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
